Kornitzer Capital Management Inc. KS Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,299 shares of the medical research company's stock after selling 9,963 shares during the period. Kornitzer Capital Management Inc. KS's holdings in IQVIA were worth $9,926,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. American National Bank & Trust bought a new stake in IQVIA in the 1st quarter valued at about $26,000. Golden State Wealth Management LLC lifted its position in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the fourth quarter worth $39,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth $44,000. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on IQV. Truist Financial lowered their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. UBS Group lowered their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Barclays reduced their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Stock Down 1.5%

IQV traded down $2.37 on Friday, hitting $160.88. The company had a trading volume of 2,306,149 shares, compared to its average volume of 1,672,521. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The stock has a fifty day simple moving average of $152.66 and a 200-day simple moving average of $171.09. The firm has a market capitalization of $27.83 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.76 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same period last year, the business posted $2.54 earnings per share. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.